Diaceutics PLC Transfer of Shares and Director/PDMR Shareholding (8262U)
April 08 2021 - 3:49AM
UK Regulatory
TIDMDXRX
RNS Number : 8262U
Diaceutics PLC
08 April 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Transfer of Shares and Director/PDMR/PCA Shareholding
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, has today been informed that Delia Keeling, wife of Peter
Keeling, the Chief Executive Officer and a PCA, has made the
following transfers, of a total of 250,000 ordinary shares of
GBP0.002 each in the Company ("Ordinary Shares") for nil
consideration to the following persons:
-- 100,000 Ordinary Shares to Robyn Keeling, wife of Ryan
Keeling, the Chief Innovation Officer, also a PCA;
-- 50,000 Ordinary Shares to Philip White, the Chief Financial Officer; and
-- 100,000 Ordinary Shares to certain family friends.
As a result of these transfers, the beneficial holdings of the
following directors and their connected parties in the Ordinary
Shares of the Company are as follows:
-- Peter Keeling, 17,252,049 Ordinary Shares, representing 20.52
% of the Company's issued share capital;
-- Ryan Keeling, 2,990,643 Ordinary Shares, representing 3.56 %
of the Company's issued share capital; and
-- Philip White, 1,956,389 Ordinary Shares, representing 2.33 %
of the Company's issued share capital.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0)207 397 8900
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - our Proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. Diaceutics has
worked on every precision medicine brought to market and provides
solutions to 36 of the world's leading pharmaceutical companies.
DXRX - the Diagnostic Network (R) provides unrivalled access to
deep analysis and insights from the world's largest repository of
diagnostic testing data on one secure platform.
About DXRX - The Diagnostic Network(R)
DXRX is Diaceutics' proprietary diagnostic network for precision
medicine. DXRX is an end-to-end solution for the development and
commercialisation of Precision Medicine diagnostics. The platform
enables a vibrant marketplace where all stakeholders in Precision
Medicine come to find trusted partners and collaborations in a
secure, standardised way. DXRX provides access to a pipeline of
global diagnostic testing data on one secure platform.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ --------------------------------------------------------------------------------------------------
a. Name Delia Keeling
------------------------------------------------------
2 Reason for notification
------------------------------------------ ------------------------------------------------------
a. Position/Status PCA, wife of Peter Keeling
------------------------------------------ ------------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ --------------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP0.002
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ------------------------------------------------------
b. Nature of the Transfer of Shares to four individual persons
transaction
------------------------------------------ ------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ ------------------------
Nil 100,000
-------------------------------------------------------------------------- -----------------------
Nil 50,000
-------------------------------------------------------------------------- -----------------------
Nil 50,000
-------------------------------------------------------------------------- -----------------------
Nil 50,000
-------------------------------------------------------------------------- -----------------------
Total 250,000
-------------------------------------------------------------------------- -----------------------
e. Date of the transaction 6 April 2021
------------------------------------------ ------------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------------ ------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ -----------------------------------------------------------------------------------------
a. Name Robyn Keeling
---------------------------------------------
2 Reason for notification
------------------------------------------ ---------------------------------------------
a. Position/Status PCA, Wife of Ryan Keeling
------------------------------------------ ---------------------------------------------
b. Initial notification/ Initial
Amendment
---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ -----------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP0.002
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ---------------------------------------------
b. Nature of the Receipt of shares from Delia Keeling
transaction
------------------------------------------ ---------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ --------------------
Nil 100,000
---------------------------------------------------------------------- ------------------
e. Date of the transaction 6 April 2021
------------------------------------------ ---------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------------ ---------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ -----------------------------------------------------------------------------------------
a. Name Philip White
---------------------------------------------
2 Reason for notification
------------------------------------------ ---------------------------------------------
a. Position/Status Chief Financial Officer
------------------------------------------ ---------------------------------------------
b. Initial notification/ Initial
Amendment
---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ -----------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP0.002
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ---------------------------------------------
b. Nature of the Receipt of shares from Delia Keeling
transaction
------------------------------------------ ---------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ --------------------
Nil 50,000
---------------------------------------------------------------------- ------------------
e. Date of the transaction 6 April 2021
------------------------------------------ ---------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------------ ---------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSSMSAAEFSELL
(END) Dow Jones Newswires
April 08, 2021 04:49 ET (08:49 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
